Cipla Framtida tillväxt
Future kriterier kontrolleras 1/6
Cipla förväntas öka intäkter och intäkter med 13.7% respektive 10.4% per år. EPS förväntas tillväxt med 13.7% per år. Avkastningen på eget kapital förväntas bli 13.1% om 3 år.
Viktig information
13.7%
Tillväxttakt i vinsten
13.71%
Tillväxttakt för EPS
| Pharmaceuticals vinsttillväxt | 16.3% |
| Intäkternas tillväxttakt | 10.4% |
| Framtida avkastning på eget kapital | 13.13% |
| Bevakning av analytiker | Good |
| Senast uppdaterad | 21 May 2026 |
Senaste uppdateringarna om framtida tillväxt
Analysartikel • May 16
Cipla Limited Just Missed EPS By 7.0%: Here's What Analysts Think Will Happen Next
Cipla Limited ( NSE:CIPLA ) missed earnings with its latest annual results, disappointing overly-optimistic...Analysartikel • Jan 28
Cipla Limited Just Missed EPS By 48%: Here's What Analysts Think Will Happen Next
The analysts might have been a bit too bullish on Cipla Limited ( NSE:CIPLA ), given that the company fell short of...Analysartikel • Nov 02
Analyst Estimates: Here's What Brokers Think Of Cipla Limited (NSE:CIPLA) After Its Second-Quarter Report
Cipla Limited ( NSE:CIPLA ) just released its latest quarterly results and things are looking bullish. Results were...Recent updates
Analysartikel • May 16
Cipla Limited Just Missed EPS By 7.0%: Here's What Analysts Think Will Happen Next
Cipla Limited ( NSE:CIPLA ) missed earnings with its latest annual results, disappointing overly-optimistic...
Uppdatering av berättelse • Apr 27
CIPLA: New CEO, US Respiratory Launch And Biologics Venture Will Steady Outlook
Analysts now place Cipla's fair value at ₹1,429.83, a small move from ₹1,427.58. This reflects refreshed assumptions around revenue growth, profit margin and future P/E expectations.Uppdatering av berättelse • Apr 12
CIPLA: New CEO And Biologics Venture Will Support Stronger Outlook
Cipla's analyst fair value estimate has been adjusted slightly from about ₹1,436.58 to ₹1,427.58, reflecting updated assumptions around revenue growth, profit margins and future P/E expectations according to analysts. What's in the News Cipla plans a board meeting on May 13, 2026, to review standalone and consolidated audited financial results for the quarter and year ended March 31, 2026, and to consider a final dividend for the year, if any (company filing).Uppdatering av berättelse • Mar 27
CIPLA: New CEO And Biologics Venture Will Support Stronger Long Term Outlook
Analysts have trimmed Cipla's implied fair value price target slightly from ₹1,446.31 to ₹1,436.58, reflecting updated views on its revenue growth, profit margin outlook, and future P/E assumptions. What's in the News A board meeting is scheduled for 19 Mar 2026 to consider appointing P R Ramesh, Lead Independent Director, as Vice Chairman, and to take up the planned exit of Independent Director Robert Stewart after completion of his current term, along with other matters (Key Developments).Uppdatering av berättelse • Mar 13
CIPLA: Pfizer Alliance And CEO Transition Will Shape Steady Forward Outlook
Analysts have kept their Cipla price target unchanged at ₹1,446.31, reflecting consistent assumptions on discount rate, revenue growth, profit margin and future P/E in their models. What's in the News Cipla has agreed to a 60:40 joint venture with Kemwell Biopharma in India to develop, obtain licenses for, manufacture, commercialise, import and export biologic products, with scope to license or outsource these activities (company announcement).Uppdatering av berättelse • Feb 27
CIPLA: Pfizer Tie-Up And Leadership Shift Will Shape Balanced Outlook
Analysts have trimmed their price target on Cipla by about ₹10 to reflect slightly softer assumptions around long term revenue growth and profit margins, while keeping the P/E framework broadly unchanged. What's in the News Pfizer India and Cipla entered into a partnership under which Cipla will exclusively market and distribute four Pfizer brands in India, including Corex Dx, Corex LS, Dolonex, Neksium and Dalacin C, while Pfizer continues to manufacture and supply these medicines (Key Developments).Uppdatering av berättelse • Feb 13
CIPLA: Pfizer Partnership And Upcoming Results Will Guide Balanced Future Expectations
Analysts have trimmed their price target for Cipla slightly to ₹1,456 from about ₹1,459, reflecting updated assumptions on discount rate, revenue growth, profit margin and future P/E that are broadly in line with prior views. What's in the News Pfizer India and Cipla entered into a partnership under which Cipla will exclusively market and distribute four Pfizer brands in India, covering Corex Dx and Corex LS cough syrups, Dolonex (NSAID), Neksium (PPI) and Dalacin C (oral antibiotic).Uppdatering av berättelse • Jan 30
CIPLA: Pfizer Alliance And Upcoming Results Will Shape Measured Future Upside Potential
Analysts have revised their fair value estimate for Cipla to ₹1,458.53, down from ₹1,657.58, citing updated assumptions for revenue growth, profit margins and future P/E multiples. What's in the News Cipla has scheduled a board meeting on Jan 23, 2026, at 11:00 Indian Standard Time to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (company filing).Analysartikel • Jan 28
Cipla Limited Just Missed EPS By 48%: Here's What Analysts Think Will Happen Next
The analysts might have been a bit too bullish on Cipla Limited ( NSE:CIPLA ), given that the company fell short of...Analysartikel • Jan 17
The Market Doesn't Like What It Sees From Cipla Limited's (NSE:CIPLA) Earnings Yet
With a price-to-earnings (or "P/E") ratio of 20.7x Cipla Limited ( NSE:CIPLA ) may be sending bullish signals at the...Uppdatering av berättelse • Jan 16
CIPLA: Pfizer Partnership And Leadership Transition Will Support Future Upside Potential
Analysts have slightly reduced their fair value estimate for Cipla to ₹1,658 from ₹1,677, citing updated assumptions that combine modestly higher revenue growth expectations with some pressure on profit margins and a marginally adjusted future P/E multiple. What's in the News A board meeting is scheduled on January 23, 2026, to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Analysartikel • Dec 29
We Think Cipla (NSE:CIPLA) Can Stay On Top Of Its Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysartikel • Nov 20
Does Cipla (NSE:CIPLA) Deserve A Spot On Your Watchlist?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Analysartikel • Nov 02
Analyst Estimates: Here's What Brokers Think Of Cipla Limited (NSE:CIPLA) After Its Second-Quarter Report
Cipla Limited ( NSE:CIPLA ) just released its latest quarterly results and things are looking bullish. Results were...Analysartikel • Sep 24
Cipla Limited's (NSE:CIPLA) Prospects Need A Boost To Lift Shares
With a price-to-earnings (or "P/E") ratio of 22.9x Cipla Limited ( NSE:CIPLA ) may be sending bullish signals at the...Analysartikel • Sep 06
Cipla (NSE:CIPLA) Seems To Use Debt Quite Sensibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Uppdatering av berättelse • Sep 04
Emerging Markets And Chronic Therapies Will Open New Horizons
With consensus forecasts for both revenue growth (8.4% p.a.) and net profit margin (15.92%) remaining steady, Cipla's Analyst Price Target was left unchanged at ₹1677. What's in the News Cipla is significantly expanding its US manufacturing capacity with an 83,000-square-foot addition at its Fall River, Massachusetts facility, focusing on complex respiratory products, and will utilize advanced technology to enhance production and efficiency.Analysartikel • Jul 13
Here's Why Cipla (NSE:CIPLA) Has Caught The Eye Of Investors
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Analysartikel • Jun 03
Here's Why Cipla (NSE:CIPLA) Can Manage Its Debt Responsibly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Ny berättelse • Nov 10
Aspirational Inhalation Launches And African Expansion Propel Growth Ambitions
Planned respiratory therapies and product launches could drive increased revenue and enhance the chronic therapy segment's growth.Prognoser för vinst- och omsättningstillväxt
| Datum | Intäkter | Intäkter | Fritt kassaflöde | Kassaflöde från rörelsen | Genomsnittligt Antal analytiker |
|---|---|---|---|---|---|
| 3/31/2029 | 378,943 | 57,759 | 37,701 | 55,901 | 14 |
| 3/31/2028 | 346,374 | 51,196 | 36,108 | 49,851 | 35 |
| 3/31/2027 | 310,811 | 41,864 | 30,077 | 43,810 | 35 |
| 3/31/2026 | 277,117 | 38,792 | 9,048 | 39,400 | N/A |
| 12/31/2025 | 279,672 | 45,464 | N/A | N/A | N/A |
| 9/30/2025 | 279,658 | 54,411 | 27,544 | 42,949 | N/A |
| 6/30/2025 | 274,796 | 53,925 | N/A | N/A | N/A |
| 3/31/2025 | 272,674 | 52,725 | 34,653 | 50,050 | N/A |
| 12/31/2024 | 267,201 | 49,897 | N/A | N/A | N/A |
| 9/30/2024 | 262,642 | 44,751 | 29,520 | 45,008 | N/A |
| 6/30/2024 | 258,922 | 43,035 | N/A | N/A | N/A |
| 3/31/2024 | 255,367 | 41,216 | 27,846 | 41,339 | N/A |
| 12/31/2023 | 251,163 | 37,082 | N/A | N/A | N/A |
| 9/30/2023 | 243,407 | 34,532 | 25,988 | 37,924 | N/A |
| 6/30/2023 | 235,108 | 31,112 | N/A | N/A | N/A |
| 3/31/2023 | 225,593 | 28,019 | 20,736 | 32,377 | N/A |
| 12/31/2022 | 222,187 | 26,383 | N/A | N/A | N/A |
| 9/30/2022 | 218,874 | 25,660 | 20,120 | 29,160 | N/A |
| 6/30/2022 | 216,105 | 24,884 | N/A | N/A | N/A |
| 3/31/2022 | 217,078 | 25,168 | 26,285 | 33,259 | N/A |
| 12/31/2021 | 210,718 | 25,681 | N/A | N/A | N/A |
| 9/30/2021 | 207,616 | 25,876 | 28,362 | 37,113 | N/A |
| 6/30/2021 | 202,801 | 25,417 | N/A | N/A | N/A |
| 3/31/2021 | 191,205 | 24,049 | 29,418 | 37,552 | N/A |
| 12/31/2020 | 188,779 | 22,374 | N/A | N/A | N/A |
| 9/30/2020 | 180,802 | 18,403 | 23,627 | 31,968 | N/A |
| 6/30/2020 | 174,377 | 16,462 | N/A | N/A | N/A |
| 3/31/2020 | 170,805 | 15,465 | 20,684 | 30,685 | N/A |
| 12/31/2019 | 171,206 | 16,678 | N/A | N/A | N/A |
| 9/30/2019 | 167,572 | 16,489 | N/A | 25,720 | N/A |
| 6/30/2019 | 163,733 | 15,546 | N/A | N/A | N/A |
| 3/31/2019 | 163,232 | 15,277 | N/A | 16,911 | N/A |
| 12/31/2018 | 155,224 | 13,391 | N/A | N/A | N/A |
| 9/30/2018 | 154,287 | 14,074 | N/A | N/A | N/A |
| 6/30/2018 | 154,992 | 14,530 | N/A | N/A | N/A |
| 3/31/2018 | 151,053 | 14,105 | N/A | 14,628 | N/A |
| 12/31/2017 | 147,618 | 11,701 | N/A | N/A | N/A |
| 9/30/2017 | 144,951 | 11,444 | N/A | N/A | N/A |
| 6/30/2017 | 141,637 | 10,762 | N/A | N/A | N/A |
| 3/31/2017 | 143,340 | 10,064 | N/A | 23,818 | N/A |
| 12/31/2016 | 142,509 | 11,213 | N/A | N/A | N/A |
| 9/30/2016 | 137,547 | 10,071 | N/A | N/A | N/A |
| 6/30/2016 | 134,335 | 12,219 | N/A | N/A | N/A |
| 3/31/2016 | 135,480 | 13,600 | N/A | 17,408 | N/A |
| 12/31/2015 | 135,044 | 16,847 | N/A | N/A | N/A |
| 9/30/2015 | 131,633 | 16,694 | N/A | N/A | N/A |
| 6/30/2015 | 124,782 | 15,368 | N/A | N/A | N/A |
Analytiker Framtid Tillväxt Prognoser
Intäkter kontra sparande: CIPLA s prognostiserade vinsttillväxt ( 13.7% per år) är över sparkvoten ( 6.9% ).
Resultat vs marknad: CIPLA s intäkter ( 13.7% per år) förväntas växa långsammare än marknaden för Indian ( 16.2% per år).
Höga tillväxtresultat: CIPLA s intäkter förväntas växa, men inte avsevärt.
Intäkt vs marknad: CIPLA s intäkter ( 10.4% per år) förväntas växa långsammare än marknaden för Indian ( 10.7% per år).
Hög tillväxtintäkter: CIPLA s intäkter ( 10.4% per år) förväntas växa långsammare än 20% per år.
Tillväxtprognoser för vinst per aktie
Framtida avkastning på eget kapital
Framtida ROE: CIPLA s avkastning på eget kapital förväntas bli låg om 3 år ( 13.1 %).
Upptäck tillväxtföretag
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/24 16:49 |
| Aktiekurs vid dagens slut | 2026/05/22 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2026/03/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Cipla Limited bevakas av 56 analytiker. 35 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Gaurav Tinani | Ambit Capital |
| null null | Anand Rathi Shares and Stock Brokers Limited |